Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Anti-rheumatic Drugs

被引：0

作者：

Mease, Philip ^{[1
]}

Lertratanakul, Apinya ^{[2
]}

Strober, Bruce ^{[3
,4
]}

Tsuji, Shigeyoshi ^{[5
]}

Richette, Pascal ^{[6
]}

Lovan, Charlie ^{[2
]}

Feng, Dai ^{[2
]}

Anderson, Jaclyn K. ^{[2
]}

Van den Bosch, Filip ^{[7
]}

机构：

[1] Seattle Rheumatol Associates PLLC, Seattle, WA USA

[2] AbbVie Inc, N Chicago, IL USA

[3] Yale Univ, Sch Med, New Haven, CT USA

[4] Cent Connecticut Dermatol, New Haven, CT USA

[5] Natl Hosp Org, Osaka Minami Med Ctr, Dept Orthopaed Rheumatol, Osaka, Japan

[6] Lariboisiere Hosp, Dept Rheumatol, Paris, France

[7] Ghent Univ Hosp, Ghent, Belgium

来源：

ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷

关键词：

INADEQUATE RESPONSE; DOUBLE-BLIND; SAFETY;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1356

引用

页数：3

共 50 条

[31] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
Hiromi Shimada
Tomohiro Kameda
Kenji Kanenishi
Nobuyuki Miyatake
Shusaku Nakashima
Risa Wakiya
Mikiya Kato
Taichi Miyagi
Mai Mahmoud Fahmy Mansour
Toshiyuki Hata
Norimitsu Kadowaki
Hiroaki Dobashi
Clinical Rheumatology, 2019, 38 : 1453 - 1458
[32] SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Van Vollenhoven, R.
Hall, S.
Wells, A. F.
Meerwein, S.
Song, Y.
Suboticki, J.
Fleischmann., R. M.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1290 - 1291
[33] Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs
van Vollenhoven, Ronald
Hall, Stephen
Wells, Alvin
Meerwein, Sebastian
Song, Yanna
Suboticki, Jessica
Fleischmann, Roy
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3534 - 3536
[34] Healthcare Costs in Psoriatic Arthritis Patients Newly Initiated On a Biologic Disease-Modifying Anti-Rheumatic Drug or Methotrexate.
Zhang, Frank
Hiscock, Robert
Curtis, Jeffrey
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S780 - S780
[35] Pharmacogenetics of disease-modifying anti-rheumatic drugs
Tanaka, E
Taniguchi, A
Urano, W
Yamanaka, H
Kamatani, N
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (02): : 233 - 247
[36] SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS ON THE TREATMENT WITH BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
Hasegawa, E.
Ito, S.
Kurosawa, Y.
Taniguchi, S.
Kobayashi, D.
Abe, A.
Otani, H.
Nakazono, K.
Murasawa, A.
Narita, I.
Ishikawa, H.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 985 - 985
[37] Disease-modifying anti-rheumatic drugs - Cyclosporin
Chaudhuri, K
Torley, H
Madhok, R
BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (09): : 1016 - 1021
[38] EVALUATION OF ADHERENCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH INFLAMMATORY ARTHRITIS
Lim, Y. C.
Teo, W. G.
Eng, M. N.
Cheen, H. M.
Tay, X. Y.
Yeo, S. I.
Lim, T. G.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1800 - 1800
[39] ADHERENCE TO BIOLOGIC AND CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Mishra, P.
VALUE IN HEALTH, 2018, 21 : S198 - S198
[40] Summary of indirect comparisons to evaluate efficacy of baricitinib with targeted synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Emery, P.
Dudler , J.
Smolen, J.
Zerbini, C.
Burmester, G.
Fautrel, B.
van de Laar, M.
Fleischmann, R.
Fakhouri, W.
De Leonardis, F.
Zhu, B.
Kadziola, Z.
De La Torre, I
Perrier, C.
Taylor, P.
SWISS MEDICAL WEEKLY, 2019, : 7S - 8S

← 1 2 3 4 5 →